On Nov. 24, 2021, Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route.

The filing included clinical data from two pivotal Phase 3 clinical trials: PREVENT-19, which included 30,000 participants in the U.S. and Mexico and demonstrated 100% protection against moderate and severe disease and 90.4% efficacy; and a trial of 15,000 participants in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall.